These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30768157)

  • 21. Cardiotoxicity among adult survivors suffered from childhood malignancies.
    Petropoulos AC; Moschovi M
    Hell J Nucl Med; 2019; 22 Suppl 2():34-40. PubMed ID: 31802042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiotoxicity of oncological treatment in children.
    Kucharska W; Negrusz-Kawecka M; Gromkowska M
    Adv Clin Exp Med; 2012; 21(3):281-8. PubMed ID: 23214190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High risk of symptomatic cardiac events in childhood cancer survivors.
    van der Pal HJ; van Dalen EC; van Delden E; van Dijk IW; Kok WE; Geskus RB; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC
    J Clin Oncol; 2012 May; 30(13):1429-37. PubMed ID: 22473161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac Imaging in Oncology Patients in Europe: a Model for Advancement of CV Safety and Development of Comprehensive CV Care.
    López-Fernández T
    J Cardiovasc Transl Res; 2020 Jun; 13(3):490-494. PubMed ID: 32583314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies.
    Bychowski J; Sobiczewski W
    Cancer Med; 2023 Jul; 12(13):14545-14555. PubMed ID: 37102247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic cardiovascular toxicity in the older oncology patient population.
    Findlay SG; Gill JH; Plummer R; DeSantis C; Plummer C
    J Geriatr Oncol; 2019 Sep; 10(5):685-689. PubMed ID: 30733001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
    Brown SA; Ray JC; Herrmann J
    J Cardiovasc Transl Res; 2020 Jun; 13(3):402-416. PubMed ID: 32253744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-related cardiotoxicity in survivors of childhood cancer.
    Lipshultz SE; Cochran TR; Franco VI; Miller TL
    Nat Rev Clin Oncol; 2013 Dec; 10(12):697-710. PubMed ID: 24165948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
    Narayan V; Ky B
    Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Toxicities in Pediatric Cancer Survivors.
    Ryan TD; Nagarajan R; Godown J
    Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
    Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
    Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
    Sayed N; Ameen M; Wu JC
    Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.
    Lenneman CG; Sawyer DB
    Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized Care in the Prevention of Treatment-Related Cardiac Dysfunction in Female Cancer Survivors.
    Pituskin E; Perri M; Cox-Kennett N; Andrews E; Dimitry R; McNeely M; Paterson I
    J Womens Health (Larchmt); 2019 Oct; 28(10):1384-1390. PubMed ID: 31314650
    [No Abstract]   [Full Text] [Related]  

  • 37. Metabolic Imaging in Cardio-oncology.
    Tong D; Zaha VG
    J Cardiovasc Transl Res; 2020 Jun; 13(3):357-366. PubMed ID: 31696405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac Outcomes in Survivors of Pediatric and Adult Cancers.
    Nathan PC; Amir E; Abdel-Qadir H
    Can J Cardiol; 2016 Jul; 32(7):871-80. PubMed ID: 27179545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity screening of long-term, breast cancer survivors-The CAROLE (Cardiac-Related Oncologic Late Effects) Study.
    Puckett LL; Saba SG; Henry S; Rosen S; Rooney E; Filosa SL; Gilbo P; Pappas K; Laxer A; Eacobacci K; Kapyur AN; Robeny J; Musial S; Chaudhry A; Chaudhry R; Lesser ML; Riegel A; Ramoutarpersaud S; Rahmani N; Shah A; Papas V; Dawodu T; Charlton J; Knisely JPS; Lee L
    Cancer Med; 2021 Aug; 10(15):5051-5061. PubMed ID: 34245128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.